Biomarker in Cisplatin-Based Chemotherapy for Urinary Bladder Cancer

被引：7
|
作者：
Ecke, Thorsten H. [1 ]
机构：
[1] HELIOS Hosp, Dept Urol, Pieskower Str 33, D-15526 Bad Saarow Pieskow, Germany
来源：
ADVANCES IN CANCER BIOMARKERS: FROM BIOCHEMISTRY TO CLINIC FOR A CRITICAL REVISION | 2015年 / 867卷
关键词：
Adjuvant chemotherapy; Bax; Bcl-2; Biomarker; Bladder cancer; CD40; Chemotherapy; Cisplatin; C-reactive protein (CRP); Emmprin; ERCC1; HER2/neu; Human epidermal growth factor receptor 2 (HER-2); Ki-67; MDR1; Metallothionein (MT); p53; Smac/DIABLO; Survivin; Tissue polypeptide antigen (TPA); TLX3; gene; Transcription factor TFAP2 alpha; TRANSITIONAL-CELL-CARCINOMA; GROWTH-FACTOR RECEPTOR; TISSUE POLYPEPTIDE ANTIGEN; MESSENGER-RNA EXPRESSION; METASTATIC UROTHELIAL CARCINOMA; PROVIDE PROGNOSTIC INFORMATION; TYROSINE KINASE INHIBITORS; LONG-TERM SURVIVAL; NEOADJUVANT CHEMOTHERAPY; ADJUVANT CHEMOTHERAPY;
D O I：
10.1007/978-94-017-7215-0_18
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
The treatment of metastasized bladder cancer has been evolving during recent years. Cisplatin based chemotherapy combinations are still gold standard in the treatment of advanced and metastasized bladder cancer. But new therapies are approaching. Based to this fact biological markers will become more important for decisions in bladder cancer treatment. A systematic MEDLINE search of the key words "cisplatin", "bladder cancer", "DNA marker", "protein marker", "methylation biomarker", "predictive marker", "prognostic marker" has been made. This review aims to highlight the most relevant clinical and experimental studies investigating markers for metastasized transitional carcinoma of the urothelium treated by cisplatin based regimens.
引用
收藏
页码：293 / 316
页数：24
相关论文
共 50 条
  • [1] Contemporary Use of Perioperative Cisplatin-Based Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
    Raj, Ganesh V.
    Karavadia, Saumil
    Schlomer, Bruce
    Arriaga, Yull
    Lotan, Yair
    Sagalowsky, Arthur
    Frenkel, Eugene
    CANCER, 2011, 117 (02) : 276 - 282
  • [2] Perioperative cisplatin-based chemotherapy for muscle-invasive bladder cancer: a decision analysis
    Afferi, Luca
    Jahn, Beate
    Kelkar, Amar H.
    Dijk, Stijntje W.
    Feldman, Zach M.
    Ward, Zachary J.
    Moschini, Marco
    Cathomas, Richard
    Bellmunt, Joaquim
    Gallioli, Andrea
    Breda, Alberto
    Fankhauser, Christian D.
    Mattei, Agostino
    Chang, Steven L.
    Siebert, Uwe
    WORLD JOURNAL OF UROLOGY, 2025, 43 (01)
  • [3] BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer
    Font, A.
    Taron, M.
    Gago, J. L.
    Costa, C.
    Sanchez, J. J.
    Carrato, C.
    Mora, M.
    Celiz, P.
    Perez, L.
    Rodriguez, D.
    Gimenez-Capitan, A.
    Quiroga, V.
    Benlloch, S.
    Ibarz, L.
    Rosell, R.
    ANNALS OF ONCOLOGY, 2011, 22 (01) : 139 - 144
  • [4] Predictive value of phenotypic signatures of bladder cancer response to cisplatin-based neoadjuvant chemotherapy
    Hensley, Patrick J.
    Kyprianou, Natasha
    Purdom, Matthew S.
    He, Daheng
    DiCarlo, Vincent
    Wang, Chi
    James, Andrew C.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2019, 37 (09) : 572.e1 - 572.e11
  • [5] Amifostine as protective agent in cisplatin-based chemotherapy of advanced bladder cancer
    Heidenreich, A
    Marx, FJ
    Peters, HJ
    UROLOGE-AUSGABE A, 1999, 38 (06): : 586 - 591
  • [6] Co-expression of ERCC1 and Snail is a prognostic but not predictive factor of cisplatin-based neoadjuvant chemotherapy for bladder cancer
    Kawashima, Atsunari
    Takayama, Hitoshi
    Kawamura, Norihiko
    Doi, Noriteru
    Sato, Mototaka
    Hatano, Koji
    Nagahara, Akira
    Uemura, Motohide
    Nakai, Yasutomo
    Nishimura, Kensaku
    Miyoshi, Susumu
    Kawano, Kiyoshi
    Nishimura, Kazuo
    Nonomura, Norio
    Tsujimura, Akira
    ONCOLOGY LETTERS, 2012, 4 (01) : 15 - 21
  • [7] Downregulation of topoisomerase 1 and 2 with acriflavine sensitizes bladder cancer cells to cisplatin-based chemotherapy
    Zargar, Parisa
    Koochakkhani, Shabnaz
    Hassanzadeh, Marziyeh
    Taziani, Yaghoub Ashouri
    Nasrollahi, Hamid
    Eftekhar, Ebrahim
    MOLECULAR BIOLOGY REPORTS, 2022, 49 (04) : 2755 - 2763
  • [8] Neoadjuvant or Adjuvant Chemotherapy for Bladder Cancer?
    Hupe, M. C.
    Kramer, M. W.
    Kuczyk, M. A.
    Merseburger, A. S.
    AKTUELLE UROLOGIE, 2015, 46 (03) : 242 - 247
  • [9] RNA Expression of DNA Damage Response Genes in Muscle-Invasive Bladder Cancer: Influence on Outcome and Response to Adjuvant Cisplatin-Based Chemotherapy
    Herrmann, Jonas
    Schmidt, Helena
    Nitschke, Katja
    Weis, Cleo-Aron
    Nuhn, Philipp
    von Hardenberg, Jost
    Michel, Maurice Stephan
    Erben, Philipp
    Worst, Thomas Stefan
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (08)
  • [10] Clinical outcomes following neoadjuvant cisplatin-based chemotherapy for bladder cancer in elderly compared with younger patients
    Chau, C.
    Wheater, M.
    Geldart, T.
    Crabb, S. J.
    EUROPEAN JOURNAL OF CANCER CARE, 2015, 24 (02) : 155 - 162
12345